In my view, the next big announcement shall be a big pharma partner for COVID-19. The last 4C put the discussions ongoing for at least a month. During the last conf call, the CFO refused to get drawn into a discussion or answer the analyst question on funds allocated for manufacturing in next quarters. Maybe the last fresh equity funds raise put the company in a better negotiation position, but won’t actually be needed for manufacturing if there is a big pharmaceutical partnership....
Here is an excerpt from MESOBLAST’s last 4C: “Mesoblast is in active discussions with US and other government authorities as well as potential pharmaceutical partners with respect to its plans for ramp-up of commercial manufacturing for remestemcel-L in COVID-19 ARDS.”
http://investorsmedia.mesoblast.com/static-files/04851ade-aca5-492c-9784-45ae8c772f04
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-144
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |